In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device/Diagnostics Quarterly Deal Statistics, Q2 2016

A look at financing, M&A and alliance activity April–June 2016

Executive Summary

Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.

You may also be interested in...



Medtronic Set To Compete With Abbott/St Jude In VADs After Buying HeartWare

HeartWare has found a way to pay for the expanded commercialization of its HVAD ventricular assist device and the development of its MVAD miniaturized ventricular assist device; the Boston-area VAD-maker has agreed be acquired by medtech giant Medtronic for $1.1bn in cash.

Zimmer Biomet Buys LDR To Boost Spine Revenue Growth

The $1 billion acquisition of the maker of the Mobi-C cervical disc replacement is expected to put Zimmer Biomet in a better position in the spine device market.

Medtronic Bets On Future Mazor Robotics Spine Surgery Systems

Medtronic is putting its sales and marketing power behind Israel-based Mazor Robotics with new commercial agreement and investment deals, both announced May 18.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel